CCM

Concord Medical Services
CCM
Market cap $30.3M

6.97 USD

+0.01

0.14%

At close Oct 7, 4:00 PM EDT

1 day

0.14%

5 days

-0.43%

1 month

32.76%

3 months

-25.13%

6 months

11.52%

Year to date

-39.39%

1 year

-45.55%

5 years

-70.34%

About: Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.

Employees: 727

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

196% more capital invested

Capital invested by funds: $26K [Q1] → $77.2K (+$51.1K) [Q2]

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 [Q1] → 4 (+1) [Q2]

0.04% more ownership

Funds ownership: 0.05% [Q1] → 0.1% (+0.04%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CCM.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CCM published over the past 30 days

Concord Medical Reports Financial Results for the First Half of 2024

BEIJING , Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024 [1].

Concord Medical Reports Financial Results for the First Half of 2024

Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) announces sample assay results from an additional 2 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Details of the holes are shown in Table 1. Highlights 10.8 grams p.

Canagold Completes Resource Expansion Drilling Program at New Polaris with Additional Strong Mineralization Intercepts

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

BEIJING , Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of the Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license (the "License") for its proton equipment.

Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment

Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (“Canagold” or the “Company”) (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA), announces sample assay results from an additional 26 drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Highlights of the gold mineralization that was intersected are s.

Canagold Continues to Intercept Strong Mineralization in Resource Expansion Drilling Program at New Polaris

Concord Medical Regains Compliance with NYSE Minimum Price Requirement

BEIJING , Aug. 7, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it has received a letter from the New York Stock Exchange ("NYSE") dated August 6, 2024 (the "Compliance Notice"), notifying the Company that it is no longer considered below the NYSE's continued listing criterion of a minimum average share price of US$1.00 over a 30 trading-day period (the "NYSE Minimum Price Requirement"). As previously announced, the Company received a letter from the NYSE dated February 12, 2024, notifying the Company that it was below compliance standards due to the trading price of its American Depositary Shares.

Concord Medical Regains Compliance with NYSE Minimum Price Requirement

Canagold Intercepts Strong Mineralization in First Five Resource Expansion Drill Holes at New Polaris

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) announces sample assay results from the first five drill holes from the resource expansion drill program targeting the North Zone at its 100% owned New Polaris Gold project located in northwestern British Columbia, 100 kilometers (km) south of Atlin and 60 km northeast of Juneau, Alaska. Highlights of the gold mineralization that was intersected in the initial five drill holes are sh.

Canagold Intercepts Strong Mineralization in First Five Resource Expansion Drill Holes at New Polaris

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING , July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it plans to change the ratio of its American depositary shares ("ADSs") to Class A ordinary shares (the "ADS Ratio") from the current ADS Ratio of one (1) ADS representing three (3) Class A ordinary shares to a new ADS Ratio of one (1) ADS representing thirty (30) Class A ordinary shares. The Company anticipates that the change in the ADS Ratio will be effective on July 30, 2024 (U.S. Eastern Time).

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

Canagold Resources Ltd. Announces Voting Results From Annual General Meeting

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company”) announces that at its annual general meeting of shareholders held on June 12, 2024 (the “Meeting”), all directors listed in the Information Circular dated May 9, 2024 were elected. The detailed results are as follows: Nominee Director Votes For % Votes For Votes Withheld % Votes Withheld Sofia Bianchi 93,941,380 99.46 511,258 0.54 Kadri Dagdelen 94,112,959 99.64 339,6.

Canagold Resources Ltd. Announces Voting Results From Annual General Meeting

Canagold Initiates Resource Expansion Drilling at New Polaris Project

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $CCM.T #drilling--Canagold Resources Ltd. (TSX: CCM, OTC-QB: CRCUF, Frankfurt: CANA) (the “Company” or “Canagold”), is pleased to announce that, in line with its commitment to accelerating the advancement of the New Polaris Gold project towards production, drill crews have been mobilized to the site in northern British Columbia to restart drilling operations. The 2024 drilling program includes 12,000 meters of drilling, primarily targeting high-grade mineralization a.

Canagold Initiates Resource Expansion Drilling at New Polaris Project

Concord Medical Files 2023 Annual Report on Form 20-F

BEIJING , April 19, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov.

Concord Medical Files 2023 Annual Report on Form 20-F

See News Rankings

Charts implemented using Lightweight Charts™